NO20000412L - Dipeptide compounds that inhibit leukocyte adhesion mediated by VLA-4 - Google Patents

Dipeptide compounds that inhibit leukocyte adhesion mediated by VLA-4

Info

Publication number
NO20000412L
NO20000412L NO20000412A NO20000412A NO20000412L NO 20000412 L NO20000412 L NO 20000412L NO 20000412 A NO20000412 A NO 20000412A NO 20000412 A NO20000412 A NO 20000412A NO 20000412 L NO20000412 L NO 20000412L
Authority
NO
Norway
Prior art keywords
compounds
vla
leukocyte adhesion
adhesion mediated
inhibit leukocyte
Prior art date
Application number
NO20000412A
Other languages
Norwegian (no)
Other versions
NO20000412D0 (en
Inventor
Eugene D Thorsett
Christopher M Semko
Michael A Pleiss
Andrei W Konradi
Francine S Grant
Darren B Dressen
Reinhardt Bernhard Baudy
Original Assignee
Elan Pharm Inc
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc, American Home Prod filed Critical Elan Pharm Inc
Publication of NO20000412D0 publication Critical patent/NO20000412D0/en
Publication of NO20000412L publication Critical patent/NO20000412L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Det er beskrevet forbindelser som binder VLA-4. Noen av disse forbindelsene inhiberer også leukocytt-adhesjon og spesielt leukocytt-adhesjon - - mediert av VLA-4. Slike forbindelser er nyttige for behandling av inflammatoriske sykdommer i en pattedyrpasient, for eksempel et menneske, hvori sykdommen for eksempel kan være astma, Alzheimer's sykdom, aterosklerose, AIDS-demens, diabetes, inflammatorisk tarmsykdom, leddgikt, vevstransplantasjon, tumor- metastase og myokardial ischemi. Forbindelsene kan også bli administrert for behandling av inflammatoriske hjernesykdommer, så som multippel sklerose.Compounds that bind VLA-4 are described. Some of these compounds also inhibit leukocyte adhesion and especially leukocyte adhesion mediated by VLA-4. Such compounds are useful for the treatment of inflammatory diseases in a mammalian patient, for example a human, in which the disease may be, for example, asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. . The compounds may also be administered for the treatment of inflammatory brain diseases, such as multiple sclerosis.

NO20000412A 1997-07-31 2000-01-27 Dipeptide compounds that inhibit leukocyte adhesion mediated by VLA-4 NO20000412L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90441597A 1997-07-31 1997-07-31
PCT/US1998/015314 WO1999006435A1 (en) 1997-07-31 1998-07-30 Dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4

Publications (2)

Publication Number Publication Date
NO20000412D0 NO20000412D0 (en) 2000-01-27
NO20000412L true NO20000412L (en) 2000-03-24

Family

ID=25419114

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20000412A NO20000412L (en) 1997-07-31 2000-01-27 Dipeptide compounds that inhibit leukocyte adhesion mediated by VLA-4

Country Status (14)

Country Link
EP (1) EP0994895A1 (en)
JP (1) JP2001512137A (en)
KR (1) KR20010022412A (en)
CN (1) CN1265673A (en)
AR (1) AR016387A1 (en)
AU (1) AU8661298A (en)
BR (1) BR9811599A (en)
CA (1) CA2291475A1 (en)
HU (1) HUP0002682A3 (en)
IL (1) IL133642A0 (en)
NO (1) NO20000412L (en)
PL (1) PL338554A1 (en)
WO (1) WO1999006435A1 (en)
ZA (1) ZA986834B (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221888B1 (en) 1997-05-29 2001-04-24 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
US6903075B1 (en) 1997-05-29 2005-06-07 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
JP2002501537A (en) * 1997-05-29 2002-01-15 メルク エンド カンパニー インコーポレーテッド Sulfonamides as cell adhesion inhibitors
JP2002501518A (en) * 1997-05-30 2002-01-15 セルテック セラピューティックス リミテッド Anti-inflammatory tyrosine derivative
JP2001517246A (en) 1997-06-23 2001-10-02 田辺製薬株式会社 α ▲ Lower 4 ▼ β ▲ Lower 1 ▼ Inhibitor of cell adhesion
US6455550B1 (en) * 1997-08-22 2002-09-24 Hoffmann-La Roche Inc. N-alkanoylphenylalanine derivatives
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
ES2226413T3 (en) 1998-02-26 2005-03-16 Celltech Therapeutics Limited PHENYLALANINE DERIVATIVES AS INTEGRIN ALFA-4 INHIBITORS.
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
GB9811159D0 (en) 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
GB9811969D0 (en) * 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
GB9812088D0 (en) * 1998-06-05 1998-08-05 Celltech Therapeutics Ltd Chemical compounds
US6685617B1 (en) 1998-06-23 2004-02-03 Pharmacia & Upjohn Company Inhibitors of α4β1 mediated cell adhesion
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
US6333340B1 (en) * 1998-08-14 2001-12-25 Gpi Nil Holdings, Inc. Small molecule sulfonamides for vision and memory disorders
US6339101B1 (en) * 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9821222D0 (en) 1998-09-30 1998-11-25 Celltech Therapeutics Ltd Chemical compounds
GB9825652D0 (en) 1998-11-23 1999-01-13 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
CA2362831C (en) * 1999-02-18 2008-10-07 F. Hoffmann-La Roche Ag Thioamide derivatives
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
CZ2002518A3 (en) * 1999-08-13 2002-05-15 Biogen, Inc. Cellular adhesion inhibitors and pharmaceutical preparations in which they are comprised
DE60035204T2 (en) * 1999-09-24 2008-02-21 Genentech, Inc., South San Francisco tyrosine
US6534513B1 (en) 1999-09-29 2003-03-18 Celltech R&D Limited Phenylalkanoic acid derivatives
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
NZ518886A (en) 1999-12-28 2004-02-27 Pfizer Prod Inc Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
ATE375330T1 (en) 2000-04-17 2007-10-15 Ucb Pharma Sa ENAMINE DERIVATIVES AS CELL ADHESION MOLECULES
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
US6740654B2 (en) 2000-07-07 2004-05-25 Celltech R & D Limited Squaric acid derivatives
US6689781B2 (en) 2000-07-21 2004-02-10 Elan Pharmaceuticals, Inc. Phenylalanine derivatives as alpha 4 integrin inhibitors
CA2417059A1 (en) 2000-08-02 2002-02-07 Celltech R&D Limited 3-substituted isoquinolin-1-yl derivatives
MY129000A (en) 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
JP2004526733A (en) * 2001-03-20 2004-09-02 メルク　エンド　カムパニー　インコーポレーテッド Substituted N-arylsulfonyl-proline derivatives as potent cell adhesion inhibitors
MY140707A (en) 2002-02-28 2010-01-15 Mitsubishi Tanabe Pharma Corp Process for preparing a phenylalanine derivative and intermediates thereof
JP2007531735A (en) * 2004-04-01 2007-11-08 エラン ファーマシューティカルズ，インコーポレイテッド Steroid saving agents and methods of using the saving agents
CA2714335A1 (en) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
CN102057054B (en) 2008-04-11 2015-06-10 梅里麦克制药股份有限公司 Human serum albumin linkers and conjugates thereof
EP2774919A1 (en) * 2013-03-06 2014-09-10 Pharmeste S.R.L. In Liquidazione Novel sulfonamide TRPA1 receptor antagonists
JP6280912B2 (en) 2013-03-14 2018-02-14 武田薬品工業株式会社 Heterocyclic compounds
WO2015002230A1 (en) 2013-07-03 2015-01-08 武田薬品工業株式会社 Amide compound
WO2015002231A1 (en) * 2013-07-03 2015-01-08 武田薬品工業株式会社 Heterocyclic compound

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU693143B2 (en) * 1993-12-06 1998-06-25 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors

Also Published As

Publication number Publication date
PL338554A1 (en) 2000-11-06
EP0994895A1 (en) 2000-04-26
CN1265673A (en) 2000-09-06
KR20010022412A (en) 2001-03-15
AR016387A1 (en) 2001-07-04
ZA986834B (en) 2000-05-02
AU8661298A (en) 1999-02-22
HUP0002682A3 (en) 2001-12-28
NO20000412D0 (en) 2000-01-27
IL133642A0 (en) 2001-04-30
WO1999006435A1 (en) 1999-02-11
HUP0002682A1 (en) 2001-07-30
JP2001512137A (en) 2001-08-21
BR9811599A (en) 2000-09-19
CA2291475A1 (en) 1999-02-11

Similar Documents

Publication Publication Date Title
NO20000412L (en) Dipeptide compounds that inhibit leukocyte adhesion mediated by VLA-4
NO20000414L (en) Benzyl compounds that inhibit leukocyte adhesion mediated by VLA-4
NO20000452L (en) Sulfonylated dipeptide compounds that inhibit leukocyte adhesion mediated by VLA-4
NO20000451L (en) Compounds that inhibit leukocyte adhesion mediated by VLA-4
NO20000413L (en) Carbamyloxy compounds that inhibit leukocyte adhesion mediated by VLA-4
NO20000410L (en) Dipeptide and related compounds that inhibit leukocyte adhesion mediated by VLA-4
NO20000411L (en) 4-Amino-phenylalamine compounds that inhibit leukocyte adhesion mediated by VLA-4
NO20000450L (en) Substituted phenylalanine compounds that inhibit leukocyte adhesion mediated by VLA-4
MXPA01007335A (en) Acyl derivatives which treat vla-4 related disorders.
HK1072608A1 (en) Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
NO20082002L (en) Pyrimidinylamide compounds that inhibit leukocyte adhesion mediated by VLA-4
TW200603788A (en) Multivalent vla-4 antagonists comprising polymer moieties
WO2000043354A3 (en) Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4
EA200401561A1 (en) HETEROARRYLIC COMPOUNDS THAT INHIBIT MEDIATED ГР4-INTEGRINES leukocyte adhesion
WO2002008203A3 (en) 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by vla-4
ZA200803016B (en) Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4
WO2000043371A3 (en) Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4
AU3246600A (en) Alpha-aminoacetic acid derivatives useful as alpha 4 beta 7 receptor antagonists
WO2002008201A3 (en) Beta-amino acid derivatives-inhibitors of leukocyte adhesion mediated by vla-4
WO2000043413A3 (en) Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application